cyrilzakka/clinical-trials huggingface dataset:
Norepinephrine Prevent Post-induction Hypotension in High-risk Patients

The investigators aimed to investigate the effects of continuous infusion of norepinephrine before and after general anesthesia induction on the occurrence of post-induction hypotension.

Intraoperative hypotension is common after general anesthesia induction and is associated with adverse postoperative events. Norepinephrine is one of the most applied vasopressors in clinical to treat intraoperative hypotension. Due to the absence of effective measures for predicting intraoperative hypotension, infusing norepinephrine before and during anesthesia induction may reduce intraoperative hypotension. There is currently a lack of research regarding whether continuous norepinephrine infusion before and during the induction of general anesthesia can mitigate or prevent post-induction hypotension. The investigators aim to investigate the effects of continuous infusion of norepinephrine before and after general anesthesia induction on the occurrence of post-induction hypotension.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged above 65 years or those above 45 years with at least one of the following preoperative cardiovascular diseases: essential hypertension, coronary artery disease, stroke, or type I/II diabetes mellitus.
* Patients who will receive major noncardiac surgery as open or laparoscopic abdominal surgeries with an anticipated operative duration over two hours, including gastrointestinal, liver, pancreatic, bladder, and uterine/adnexal surgeries.

Exclusion Criteria:

* Patients who declined to participate in the present study.
* Patients enrolled in another ongoing clinical study.
* Patients with systolic arterial pressure (SAP) below 90 mmHg or above 160 mmHg, or heart rate (HR) over 100 beats per minute (bpm) before anesthesia induction.
* Patients who have experienced any type of shock within 30 days before surgery.
* Patients with circulatory instability require continuous or intermittent positive inotropic and/or vasopressors within 24 hours before surgery.
* Patients receive continuous or intermittent intravenous antihypertensive agents within 24 hours before surgery.
* Patients underwent coronary artery bypass grafting, coronary angiography, or coronary stenting within 180 days before surgery.
* Patients who were diagnosed with new-onset tachyarrhythmia within 180 days before surgery, such as atrial fibrillation, atrial flutter, and premature ventricular contractions.
* Patients with preoperative alanine aminotransferase \>80 international units and/or glomerular filtration rate \< 80 ml/min within the 180 days before surgery.
* Patients are ineligible for intraoperative invasive radial artery blood pressure monitoring.
* Patients with a known history of allergy to norepinephrine.
* Patients who were planned for rapid sequence induction.
* Patients who were scheduled for awake tracheal intubation.
* Patients who were scheduled for double-lumen endotracheal intubation. Pregnant or lactating patients.
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

OBJECTIVES:

I. Determine the safety and effectiveness of R115777 in patients with metastatic pancreatic cancer.

II. Determine the response rate, time to progression, and 6 month survival rate of these patients with this treatment regimen.

III. Assess the pharmacokinetics of this treatment regimen in this patient population.

OUTLINE: This is a multicenter study.

Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Histologically confirmed adenocarcinoma of the pancreas
* Measurable metastatic disease No prior treatment for metastatic disease except immunotherapy (e.g., antibodies, vaccines, cytokines)

PATIENT CHARACTERISTICS:

* Age: 18 and over
* Performance status: ECOG 0-2
* WBC at least 4,000/mm3 OR granulocyte count at least 1,500/mm3
* Platelet count at least 100,000/mm3
* Bilirubin no greater than 2.0 mg/dL
* SGOT/SGPT no greater than 2 times normal
* Creatinine no greater than 2.0 mg/dL OR creatinine clearance at least 50 mL/min
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for 3 months after the study
* No concurrent illness or active infection which would preclude study
* No prior malignancy allowed unless disease free for the time period considered appropriate for cure of the specific cancer
* No history of allergies to imidazole compounds (e.g., fluconazole, ketoconazole, miconazole, itraconazole, clotrimazole)

PRIOR CONCURRENT THERAPY:

* No prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or thrombopoietin
* Primary neoadjuvant or adjuvant chemotherapy allowed at least 6 months prior to detection of metastatic disease
* Primary radiotherapy allowed at least 6 months prior to detection of metastatic disease
* No concurrent use of proton pump inhibitors (e.g., omeprazole)
Mindfulness-based Smoking Cessation Enhanced With Mobile Technology

The purpose of this study is to:

Aim I: Test the efficacy of a mindfulness-based text messaging program for smoking cessation ("iQuit Mindfully"), both as a standalone intervention and in combination with in-person counseling; and Aim II: Investigate the mechanisms through which mindfulness training impacts smoking cessation.

This study is a 2 X 2 randomized controlled trial to investigate the effects of the iQuit Mindfully text messaging program, both as a standalone intervention and in combination with in-person counseling (Mindfulness-based Addiction Treatment; MBAT), compared to usual care. Participants will be randomized to one of four groups based on assignment to iQuit Mindfully text messages (yes/no) and in-person MBAT (yes/no):

* Usual Care (self-help materials + nicotine patch and nicotine lozenge treatment)
* MBAT (8 weekly virtual MBAT sessions + self-help materials + nicotine patch and nicotine lozenge treatment)
* iQuit Mindfully (iQuit Mindfully text messages + self-help materials + nicotine patch and nicotine lozenge treatment)
* MBAT + iQuit Mindfully (8 weekly virtual MBAT sessions + iQuit Mindfully text messages + self-help materials + nicotine patch and nicotine lozenge treatment)

All study participants will receive self-help smoking cessation materials, including the "Clearing the Air" booklet developed by the National Cancer Institute (NCI) and a referral to the Tobacco Cessation Quitline (1-800-QUIT-NOW). All study participants will also receive nicotine patches and lozenges. Assessments will occur at baseline and weeks 1, 3, 5, and 8. Follow-up assessments will occur at weeks 12 and 24.

Eligibility Criteria:
Inclusion Criteria:

* at least 18 years of age
* current smoker with history of \>3 cigarettes/day (and expired carbon monoxide \[CO\] \>6ppm)
* motivated to quit within next 30 days
* valid home address in the greater Atlanta, GA area
* functioning telephone number
* can speak, read, and write in English

Exclusion Criteria:

* contraindication for nicotine patch or nicotine lozenge
* active substance abuse/dependence
* current suicidal ideation
* current use of tobacco cessation medications
* pregnancy, planning to become pregnant in the next 5 months, or lactation
* household member enrolled in the study
* enrolled in previous smoking cessation study based on mindfulness and/or text messaging at Georgia State University
Biomarkers in Patients With Anemia-Induced Thrombocytopenic Bleeding

This pilot study aims to gather preliminary evidence on how different hemoglobin levels impact blood biomarkers related to bleeding. The feasibility of conducting a future larger clinical trial will also be assessed. Red blood cell transfusions are part of the standard of care for patients with leukemia. This study evaluates two transfusion strategies: one that maintains hemoglobin levels above the standard-of-care threshold, reflecting current routine practice; and another that maintains hemoglobin levels above 110 g/L, which is closer to the normal hemoglobin range. The normal hemoglobin range is 120-160 g/L for females and 140-180 g/L for males. Raising hemoglobin levels closer to normal values may reduce bleeding risk.


Eligibility Criteria:
Inclusion Criteria:

1. ≥18 years old.
2. Inpatient
3. Diagnosis of acute myeloid leukemia or acute lymphocytic leukemia.
4. Less than 5 days have elapsed since the start of induction chemotherapy treatment.
5. Hemoglobin at enrolment is under 130 g/L.

Exclusion Criteria:

1. Failure to provide informed consent.
2. Unwilling to receive blood transfusions.
3. Life expectancy \<72 hours.
4. Undergoing palliative chemotherapy.
5. Requires specialized blood products (e.g., antigen-matched, irradiation, etc.).
6. Diagnosis of acute promyelocytic leukemia.
7. Diagnosis of hyperleukocytosis (a white blood cell count exceeding 100 × 10\^9/L).
8. Diagnosed with coagulopathies or ongoing treatment with therapeutic anticoagulants, aspirin or nonsteroidal anti-inflammatory drugs (history of inherited or acquired coagulation disorder, known hemolytic disease, INR \> 1.5)
9. Evidence of iron overload (ferritin \>800 ng/mL, transferrin saturation \>80%) .
CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.

Relapse is a common cause of failure in patients with B-cell malignancies after autologous stem cell transplantation. CD19-targeted CAR-T cells showed excellent therapeutic efficiency in B-cell malignancies. Investigators attempt to treat minimal residual disease (MRD)-positive B-cell Malignancies after autologous stem cell transplantation by CD19-targeted CAR-T cells and hope to explore the therapeutic effects of CD19-targeted CAR-T cell therapy.

Eligibility Criteria:
Inclusion Criteria:

1. Confirmed by pathological biopsy in patients with B-cell malignancies and treated by autologous stem cell transplantation.
2. Age 18 to 75 years old, both male and female;
3. Is expected to survive more than 3 months;
4. Physical condition is good: ECOG score≤2;
5. In group of four weeks before Canon imaging examination evaluation body tumor load, recommend line PET - CT examination.
6. General requirements autologous as basic, normal blood T lymphocytes in autologous count must \>= 0.2 x10\^9 / L;
7. No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the body;
8. Into groups to participate in voluntarily, good adherence, can cooperate test observation, childbearing age women must be 7 days before starting treatment expert pregnancy test and the results were negative, and signed a written informed consent form.

Exclusion Criteria:

1. Organ failure, such as heart: Class III and IV; liver: to Child grading of liver function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness;
2. Existing serious acute infection, uncontrollable, or have fester sex and chronic infection, wound in delay no more;
3. Patients with significant graft versus host disease (GVHD) after organ transplant history or allogeneic hematopoietic stem cell transplantation;
4. Systemic autoimmune diseases or immunodeficiency disease, patients with allergic constitution;
5. Coagulation abnormalities and severe thrombosis;
6. Pregnancy and lactation women;
7. Any other chronic disease patients who have been treated with immune agents or hormone therapy;
8. Patients who have participated in other clinical trials or other clinical trials in the past 30 days;
9. The Investigator believe the patients should not participate in this experiment.
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects

The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza antigen, in non-elderly adult and elderly subjects.


Eligibility Criteria:
Inclusion Criteria:

* Male and female volunteers 18 years of age or older

Exclusion Criteria:

* any auto-immune disease or other serious acute, chronic or progressive disease
* hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the vaccine.
* history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine.
* within the past 7 days, they have experienced: any acute disease, infections requiring systemic antibiotic or antiviral therapy.
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.

Patients be randomized in a 1:1 ratio into 2 arms to receive either acalabrutinib monotherapy (Arm A) or rituximab in combination with chlorambucil (Arm B). The primary objective of this study is to compare the efficacy of acalabrutinib relative to chlorambucil plus rituximab in subjects with previously untreated chronic lymphocytic leukemia without del(17p) or TP53 mutation.

Eligibility Criteria:
Inclusion Criteria:

* Men and women: (a) ≥65 years of age OR (b) \>18 and \<65 years of age, provided that they meet at least one of the following criteria: (i) Creatinine clearance 30 to 69 mL/min using the Cockcroft-Gault equation (iwCLL guidelines) (ii) A score higher than 6 on the Cumulative Illness Rating Score-Geriatric (CIRS G)
* ECOG performance status of 0, 1, or 2
* Diagnosis of CLL that meets published diagnostic criteria (Hallek 2018)
* Active disease per IWCLL 2018 criteria that requires treatment
* Adequate bone marrow function
* Adequate renal and hepatic function

Exclusion Criteria:

* Known detected del(17p) or TP53 mutation
* Transformation of CLL to aggressive non-Hodgkin lymphoma (NHL) (eg, Richter's transformation, PLL, or diffuse large B cell lymphoma \[DLBCL\]), or central nervous system (CNS) involvement by leukemia
* History of prior malignancy except for the following: (a) Curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study (b) Other cancers not specified above which have been curatively treated by surgery and/or radiation therapy from which subject is disease-free for ≥3 years without further treatment
* Significant cardiovascular disease
* Known history of infection with human immunodeficiency virus (HIV)
* Serologic status reflecting active hepatitis B or C infection
* Any active systemic infection (eg, bacterial, viral, or fungal infection) requiring systemic treatment
* History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
* Major surgical procedure within 30 days of first dose of study drug
* Any prior CLL-specific therapies
* Corticosteroid use \>20 mg within 1 week before first dose of study drug, except as indicated for other medical conditions
* Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists
* For women only: breastfeeding or pregnant
Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid tumors.

OBJECTIVES: I. Estimate the maximum tolerated dose (MTD) of ecteinascidin-743 (ET-743) when administered as a single intravenous infusion every 21 days in adults with solid tumors not amenable to standard therapy. II. Describe the qualitative and quantitative toxic effects of ET-743, and study the predictability, duration, intensity, onset, reversibility, and dose-relationship of these toxic effects in these patients. III. Propose a safe dose for a phase II study based on the MTD determined on this study. IV. Assess the pharmacokinetics of ET-743 at different dose levels. V. Document any antitumor effects of ET-743 in these patients.

OUTLINE: This is a multicenter study. All patients receive ET-743 IV over 3 hours every 21 days for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ET-743 until the maximum tolerated dose is determined. Patients are followed at 1 month, then every 3 months until disease progression.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study over 12 months.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed solid tumor that is not amenable to standard therapy No evidence of brain involvement or leptomeningeal disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: ANC at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin less than 1.5 mg/dL Transaminases normal (no greater than 2.5 times normal if liver metastases) Alkaline phosphatase normal (no greater than 2.5 times normal if liver or bone metastases) No history of chronic liver disease, e.g., chronic active hepatitis, cirrhosis Renal: Creatinine no greater than 1.4 mg/dL Creatinine clearance at least 60 mL/min Other: No active bacterial infection (e.g., abscess) or with fistulae No grade 2 or worse neurotoxicity No concurrent medical condition that precludes treatment No history of alcoholism, drug addiction, or psychotic disorder Not pregnant or nursing Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Colony-stimulating factors allowed for specific indications At least 4 weeks since prior biologic therapy, immunotherapy, or growth factors Chemotherapy: No prior intensive chemotherapy with bone marrow or stem cell support At least 4 weeks since chemotherapy (6 weeks since nitrosoureas, mitomycin, or high-dose carboplatin) Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since radiotherapy Concomitant palliative local radiotherapy allowed for existing lesion Surgery: Recovered from prior surgery Other: No concurrent investigational drug Concurrent prophylactic antiemetics allowed after first therapy course
CPR Education: Traditional Program Versus On-line Program

Out-of-hospital cardiac arrest (OHCA) is an important public health issue. Chang Gung Memorial Hospital, a university affiliated medical center in Taoyuan city, northern Taiwan, actively cooperated with the government policy to donate a total of 250 automated external defibrillators (AED) and to deploy them in public areas during the period of 2012 to 2014. In addition, nearly 200 courses of cardiopulmonary resuscitation (CPR) education for healthcare providers and citizens were provided.

In order to keep the skills and the abilities of emergency medical responses in these 200 and more AED recipient areas, repeated CPR education and training should be implemented. Quality assurance and regular follow-up by medical directors with professional advice and feedback can therefore be provided at the same time. Therefore, this project aims to assess the quality of emergency responses in the recipient units in the next four years via regular follow-up by medical directors with advice and feedback. Continuing medical education of both e-learning and classes, online registration system, as well as first aid supplies will be provided at the regular follow-up visits. The results of this project will provide a feasible model of quality assurance of first aid and AED implementation program in the community.

The core value of the investigation is to provide high quality, convenient, time-saving, and cost-effective CPR training model. The training proctors will either instruct laypersons or healthcare providers to watch on-line video for 18 minutes at home then practice the skills for 30 minutes in the training scene or provide standard CPR program (90 minutes in the scene) and empower them with the life-saving skills of CPR. The American Heart Association's CPR with a DVD and laerdal QCPR manikin will be used to record. Participants will be randomly allocate into either the on-line or standard method of the training program. To assess the effects of training, the participants will receive written examinations before and after the course. The investigators will also follow up with the study participants and conduct CPR skills tests at 6 and 12 months from the time of training to assess whether the subjects retain their skills or if they have an opportunity to use the skills that they learned. Information about the willing of performing CPR and satisfaction to the training will also be collected.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged 20 and over
* Adults who have not attended CPR training for at least one year prior to enrollment

Exclusion Criteria:

* unable to kneel to practice CPR
* pregnant
* unwilling to sign informed consent